Cumberland Emerging Technologies Announces New Small Business Grant Award In Collaboration with Vanderbilt University

NASHVILLE, Tenn. **(November 19, 2014)** -- The U.S. National Institutes of Health (NIH) has awarded $225,000 in support of a joint research program involving Cumberland Pharmaceuticals Inc., Cumberland Emerging Technologies, Inc. and scientists at Vanderbilt University. The Phase I grant is awarded under the Small Business Technology Transfer Research (STTR) funding mechanism.

The objective of the collaborative research program is to advance development of a novel radiosensitizing agent intended for use as adjunct therapy with radiation, for treating nonsmall cell lung cancer and other types of cancers for which radiotherapy is indicated.

On February 25, 2013, Cumberland Emerging Technologies executed an Agreement with Vanderbilt University around rights to develop the radiosensitizing technology subject of this grant award. Michael Freeman, Ph.D., at Vanderbilt University is an Inventor and the Principal Investigator of the NIH STTR Phase I grant issued September 22, 2014. In November 2014, an Agreement was executed with Vanderbilt University to provide funding and support the efforts of Dr. Freeman's team to achieve objectives proposed in the collaborative grant application.

Cumberland is providing project and grants management assistance. The company is also providing pre-formulation, product development and regulatory support to help advance this technology and create a new drug product candidate for clinical use.

About Cumberland Emerging Technologies Inc.

Cumberland Emerging Technologies Inc. (CET) is a joint initiative between Vanderbilt University, Cumberland Pharmaceuticals Inc., and the Tennessee Technology Development Corporation (TTDC). The mission of CET is to advance biomedical technologies and products conceived at academic research centers towards the commercial marketplace. CET manages the development and commercialization process for select projects, and provides critical expertise on intellectual property, regulatory, manufacturing, and market issues that are critical to successful new biomedical products.

CET has sponsored Middle Tennessee's first life sciences incubator located in downtown Nashville adjacent to the Union Station Hotel and the Frist Visual Arts Center. This Life Sciences Center provides laboratory space, equipment and other support to a growing number of tenants who specialize in medical products and research advancements. For more information, visit www.CET-Fund.com.